Lisa Argnani

17PUBLICATIONS
46CO-AUTHORS
Immunogenetics (incl. genetic immunology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Feb 13, 2026
Analytical and clinical performance of in-house and commercial real-time PCR assays for diagnosing L. infantum visceral leishmaniasis: a study from a hub center in Northern Italy.

Tommaso Gritti, Beatrice Mola, Lisa Argnani

|Jan 14, 2026
TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B-Cell Lymphoma in the Real-Life Patient Journey.

Lisa Argnani, Cinzia Pellegrini, Ombretta Annibali

|Mar 07, 2025
Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope.

Lisa Argnani, Beatrice Casadei, Pier Luigi Zinzani

|Feb 24, 2025
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study.

Beatrice Casadei, Lisa Argnani, Alessandro Broccoli

|Nov 07, 2024
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma.

Rossana Di Staso, Beatrice Casadei, Frederick L Locke

|Aug 06, 2024
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf Study.

Beatrice Casadei, Gabriele Conti, Monica Barone

Pageof 3

Frequent Collaborators

11 joint publications

Pier Luigi Zinzani

2 joint publications

Alessandro Broccoli

1 joint publications

G Carrara

1 joint publications

A Zanetti